GSK is helping pharmacists to tap into Self Care Week this November, and remind patients how they can adopt a more proactive approach in looking after their health. This includes treating ailments, such as joint pain, over the counter to take pressure off GPs where possible.
Joint pain complaints take up a significant amount of general practice resource with 57 per cent of pain presentations reported relating to joint pain[1], as well as 23 per cent of sufferers feeling as though their pain impacts their quality of life[2].
Many of these complaints and ailments could be addressed with treatment recommendations from a pharmacist with support from Voltarol.
GSK, manufacturer of Voltarol (the market leader in the pain relief topic category[3]), offers support through both its products and resources in hopes to advocate over-the-counter treatments.
The prevalence of Covid-19 infections in England rose to around one in 60 people in the week ending November 27, the Office for National Statistics said today (December 03), led higher by the dominant Delta variant rather than the newly identified Omicron.
The prevalence was up from one in 65 reported the previous week, the ONS said, adding that 99 per cent of all coronavirus infections which were sequenced were
genetically compatible with the Delta variant.
"To date, we have not identified any infections compatible with the new Omicron variant (B.1.1.529) among our survey participants," the ONS said.
Prime Minister Boris Johnson has introduced travel restrictions and some mask mandates, with a view to slowing the spread of Omicron while work is undertaken to
understand it better.
There have been 42 confirmed cases of the variant in Britain, which has mutations consistent with reduced vaccine efficacy.
His Royal Highness the Prince of Wales is to host a reception at St James's Palace in early May to celebrate exemplary work of community pharmacist during
the Coronavirus pandemic.
Up to 200 community pharmacists have been invited by Prince Charles to the event organised to "celebrate community pharmacists", which commences at 5:30pm on
Wednesday, May 4 at the London residence of the Prince of Wales.
The invitation comes in less than six months after Prince Charles praised community pharmacists for their efforts during the Covid-19 pandemic in a video message sent to the National Pharmacy Association (NPA)'s centenary dinner at Apothecaries' Hall in central London in November last year.
He said throughout the pandemic pharmacy teams' "commitment to patient care has never wavered, despite the many enormous pressures you have faced.
"During this pandemic period, we have learned, as never before, that pharmacies are one of those vital places where science and society meet. Crucially, they are about people and places, not just pills."
The National Pharmacy Association has announced the theme for this year's 'Ask Your Pharmacist Week' campaign - 'Meet Your Local Pharmacy Team'. The campaign,
scheduled for October 30 to November 6, seeks to enhance awareness of pharmacy services and initiate dialogues with local stakeholders, highlighting the role and
advantages of community pharmacy, the NPA said in a statement.
NPA has organised an array of promotional activities, spanning window displays, social media engagements, partnerships with patient groups, radio and TV interviews,
and visits to pharmacies by local dignitaries and politicians during the week.
"AYP Week 2023 will acquaint individuals with the pharmacist's skill set and the broader community pharmacy workforce, showcasing their collaborative efforts in
delivering a secure and efficient service, encompassing NHS clinical care," said Stephen Fishwick, NPA's Head of Communications. "As always, the NPA will furnish
campaign resources for our members and other participants interested in engaging with this enduring initiative."
The National Pharmacy Association (NPA) has appointed Paul Rees MBE as its new Chief Executive, with his role commencing on November 27th. Rees, currently
serving as the Chief Executive of the Royal College of Psychiatrists and having held various roles throughout his career, will succeed Mark Lyonette, who is
retiring, NPA said in a statement.
"We anticipate Paul joining the NPA after a thorough recruitment process affirmed his suitability," said Nick Kaye, Chair of NPA. "Throughout his career, including
his role at the Royal College of Psychiatrists, he has made a significant impact and achieved concrete changes in healthcare and society. I would also like to
express my appreciation to Mark for his work as Chief Executive since 2018. He still has important tasks to complete at the NPA before his retirement."
Rees has also held key positions at prominent organisations, including the Ramblers Association, National Housing Federation, Charities Aid Foundation, Association
of University Teachers, and the , besides being the Head of Communications at the Home Office.
The General Pharmaceutical Council's Fitness-to-Practise (FtP) committee has reversed its earlier decision ruling that a London pharmacist's statement,
attributing the Grenfell tragedy to "Zionist supporters of the Tory party," amounted to the propagation of anti-Semitic tropes.
In an initial 2020 hearing, the FtP committee found that a set of remarks delivered by Nazim Hussain Ali, Managing Partner of Chelsea Pharmacy Medical Clinic,
through a megaphone to a crowd assembled at a Palestinian rights rally in central London in 2017 were deemed "grossly offensive," but not classified as anti-Semitic.
Ali admitted his comments were offensive, but he was cleared of accusations of antisemitism and received a first warning on November 5, 2020.
However, the High Court overturned this decision in June 2021 following an appeal by the Professional Standards Authority as the Judge found evidence of
a "serious procedural or other irregularity" in the FtP committee's decision and instructed the GPhC to reopen the case.
The British Generic Manufacturers Association (BGMA) has sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a
new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI).
Mark Samuels, Chief Executive of BGMA said: "The Government has decided not to involve the trade body representing these medicine suppliers in its negotiations on the
voluntary scheme for branded medicine pricing (VPAS).
"We are deeply concerned by this decision. It has left us no choice but to take legal action."
"While not all generic drugs fall within VPAS, four out of ten products in the current scheme are branded generics or biosimilars. As the representative trade body
for both generic and biosimilar UK manufacturers, we must play a full part in the VPAS negotiations for the next period of the scheme from 2024 to 2028."
"The VPAS tax has risen five-fold in under two years, an unprecedented tax increase. Yet our sector currently has no input into the negotiations on future schemes or
rates; this is untenable as any decisions made on VPAS could significantly define the future of our sector in the UK and its ability to supply the NHS.
The association had raised its full participation in the negotiations with the Government last November.
The Scottish Government and Community Pharmacy Scotland have agreed to roll out next month a new national service to provide emergency access to supplies
of naloxone.
An NHS circular signed by Alison Strath, Chief Pharmaceutical Officer of Scotland, advises that the emergency supply service will be added to the community
pharmacy Public Health Service from 30 October 2023. It states that community pharmacy contractors and pharmacy teams should ensure they are familiar with the
new arrangements.
Community pharmacy contractors have been asked to ensure that pharmacy teams complete the e-learning module for naloxone emergency supply. They are also encouraged
to join webinars to support the implementation of the service which will be held on Wednesday 4 October and Tuesday 14 November at 19:30. Details of how to register
can be found at on NHS Scotland's Turas platform.
The Pharmaceutical Services Negotiating Committee (PSNC) will be hosting a Parliamentary drop-in event for MPs on Monday (14 November).
"The event will last for roughly two hours, during which MPs will have the opportunity to drop-in and have their blood pressure measured by a fully qualified
pharmacist," said the committee.
It added: "This event will be a great opportunity to talk to MPs from across the political spectrum about the incredible work pharmacies are doing up and down the
country, to demonstrate the Hypertension Case-Finding Service and to discuss the frontline role pharmacists play in delivering vital services and free, expert
advice."
The other community pharmacy bodies, including the National Pharmacy Association (NPA), the Company Chemists' Association (CCA) and the Royal Pharmaceutical Society
(RPS) will also be present on the day, providing the sector with a valuable chance to present a united front on the big issues facing contractors throughout the
country.
AAH Pharmaceuticals on Tuesday (November 15) announced the promotion of its commercial director David Bound to chief executive officer of the company.
In his 10 years in the company, Mr Bound has helped to drive growth across the AAH business, implementing new digital channels for customers, and developing
strategic partnerships with pharmaceutical manufacturers - drawing on from his vast experience in the healthcare industry, as well as in supply chain, operations,
and trading.
Commenting on his promotion, he said: "I'm delighted to be taking on this role at such a critical time for healthcare. There are many challenges affecting the
industry right now - from inflationary pressures to workforce issues - and I'm looking forward to tackling them head-on alongside my excellent team."
The Pharmaceutical Services Negotiating Committee (PSNC) will launch a new influencing campaign to build wider political support for community pharmacies
this week.
The campaign aims to ensure that MPs and Peers across Parliament understand the risks to pharmacy services that the current pressures on the sector are causing.
In a Parliamentary event held today (Tuesday 15 November) MPs and Peers heard from PSNC, LPC and other pharmacy bodies about the current situation.
PSNC briefed them on the urgent need for action to address the pressures on the sector.
The committee will be working with LPCs and contractors to organise a series of pharmacy visits for key Parliamentarians including Minsters, Committee and APPG
Members.
This is happening alongside work to develop a new vision and strategy for the community pharmacy sector, all of which is part of PSNC's strategy to lay the
ground for future CPCF negotiations.
More than three quarters of British people, who have suffered persistent ill health following a Covid-19 infection, have had to cut back or change the work
they do, according to a survey on the impact of long Covid published on Wednesday (November 9).
In the survey of 1,002 people, conducted by market research company Censuswide, some 98 per cent of long Covid sufferers said the condition had limited their ability
to work, with 78 per cent needing to cut back or change their work and 19 having ceased work altogether.
Long Covid, a collection of symptoms ranging from pain and heart palpitations to insomnia and brain fog, can last for many months after initial infection.
Britain's most recent official labour market data showed that a record proportion of people classified as "economically inactive" - neither working nor looking for a
job - were suffering from long-term sickness. In absolute terms, the number of working-age people who are long-term sick has risen by 378,000 since early 2020.
The Pharmaceutical Services Negotiating Committee (PSNC) has launched a four point plan at its parliamentary drop-in event for MPs and peers hosted on Tuesday
(15 November).
The event lasted for two hours, during which MPs had the opportunity to drop-in and have their blood pressure measured by pharmacists with experience of working on
the front-line and were briefed on the urgent need for action to address the pressures on the sector.
Outline of the four-point plan:
Resolve the funding squeeze: Community pharmacy needs an immediate funding uplift to prevent large-scale pharmacy closures, as well as emergency business relief to
get through this winter.
Tackle regulatory and other burdens: Pharmacies must be protected from medicines market shocks, supported to help them weather the workforce crisis, helped to free
up capacity and freed from red tape that does not enhance patient care.
Help pharmacies to expand their role in primary care: Pharmacies could do more to support the delivery of primary care for example through offering clinical services
for long-term conditions - like hypertension, diabetes and respiratory disease, supporting people to adopt healthier lifestyles and prevent the development of
long-term conditions, medicines optimisation, and a much wider variety of NHS vaccinations.
The widely-held concept that levels of "good" cholesterol in the blood can indicate heart disease risk is not equally true for Blacks and whites, and the measure
itself may be of less value than previously thought, according to a U.S. study published on Monday (November 21).
Various types of cholesterol are thought to have either healthy or unhealthy effects.
Low levels of so-called "good" high-density lipoprotein (HDL) cholesterol were linked with higher odds for developing cardiac problems in the long-term study - but
only in white participants, the study published in the Journal of the American College of Cardiology found.
In contradiction to what has generally been assumed, low HDL levels did not confer any higher risk of heart disease in Black people, researchers said. Among white
people, however, those with HDL levels below 40 milligrams per deciliter had a 22% higher risk for coronary heart disease compared with those whose HDL levels were
higher.
High HDL levels (above 60 mg/dL), which are thought to be protective, were not linked with lower coronary heart disease risks in either race, researchers found.
Boots UK's chief pharmacist has been encouraging people to get a flu vaccination by the end of November to help protect themselves, their loved ones and the
NHS this festive season.
Flu cases in the UK are usually highest in the winter months, from December to March. This year, the UK has seen a rise in cases earlier than usual, and therefore
Claire Nevinson, superintendent pharmacist at Boots, reminds people that it is even more important to get protected early to help reduce the risk of spreading the
virus due to increased mixing at Christmas parties and family get togethers.
Approximately 33 million people are eligible for the free NHS flu jab, including those over 50 years of age, pregnant women and those with medical conditions such as
diabetes or heart disease.
The pharmacy multiple says it offers the winter flu jab service, which is suitable for those eligible for the free NHS flu jab as well as privately, adding that it
has already administered over one million flu vaccinations this season.
Ms Nevinson explains: "December is a time to get together with friends and family to celebrate the month's festivities. It's a good idea to plan ahead to ensure you
have your flu jab, and your COVID-19 booster vaccination if you are eligible, if you've not had them already, this the best way to protect yourself and reduce the
risk of passing the viruses to others.
Recent uptake of COVID-19 vaccine booster doses in Europe has been "rather disappointing," an official said on Thursday (November 24), amid concerns that
protection against severe cases of the disease could weaken during the winter.
The European average rate of re-vaccination, or receiving booster doses, was only 29 per cent in the groups of people considered to be at highest risk, such as
the elderly and immunocompromised.
"It is of concern that those most at risk of hospitalisation or severe COVID are not adequately protected," the European Medicines Agency's head of health threats
and vaccines strategy, Marco Cavaleri, told a news briefing.
Though there have not been major increases in COVID-19 case rates in recent weeks, Cavaleri said that could change during the colder winter months.
British drug discovery company C4X Discovery said AstraZeneca had signed a licence worth up $402 million to develop an oral therapy for the treatment of
inflammatory and respiratory diseases using its NRF2 Activator programme.
The Manchester-based company said on Monday (November 28) it would receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial,
including $2 million upfront.
In addition, C4XD said it would receive a further potential $385.8 million in clinical development and commercial milestones and tiered mid-single digit royalties
upon commercialisation of any treatment.
Japanese pharmaceutical firm Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed
with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year.
It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S.
government's Medicare plan for people age 65 and over, potential side effects and cost.
One Wall Street analyst told Reuters news agency that he is not counting on measurable sales until 2024. Several estimated lecanemab may be priced at around $20,000
per year.
"Most people who this (drug) would apply to are on Medicare, and most private payers look to Medicare as they make their own (coverage) decisions. So there's a
massive roadblock in the way of all who could benefit from this treatment," said Robert Egge, Alzheimer's Association chief public policy officer.
Eisai confirmed on Tuesday (November 30) that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced
the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. It also gave new details on side effects including a dangerous type of brain
swelling and brain bleeding.
Only a day is left before community pharmacy contractors are required to complete Health Education England's Community Pharmacy Workforce Survey for 2022.
The survey closes on Wednesday (November 30).
The completion requirements are mandatory and particularly pertinent at a time when workforce challenges have become a major issue within the sector. These pressures
are being acutely felt within community pharmacy, with serious consequences for pharmacy contractors.
PSNC and the other national pharmacy bodies have called for improved workforce planning to be undertaken by the government and NHS, but for this to happen, high
quality workforce data for community pharmacy needs to be available, which will then provide a full picture of the sector's workforce, including identifying the
number of vacancies and regions where these are particularly hard to fill.
Pharmaceutical giant AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday
(November 29) as it seeks to build its pipeline of cell-based cancer treatments.
Though AstraZeneca's oncology portfolio accounted for more than a third of the company's revenue last year, it does not have an approved cell-based cancer therapy
and is behind rivals such as Novartis and Gilead.
"Neogene's leading (T-cell receptor) discovery capabilities and extensive manufacturing experience complement the cell therapy capability we have built over the
last three years," said Susan Galbraith, AstraZeneca's executive vice president of oncology research.
Cell-based treatments are a relatively new approach to treating cancer, most of which involve drawing the body's own immune cells and processing them in the lab to
target and kill cancer cells.
Neogene's approach goes one step further in that its experimental T-cell receptor therapies seek to target DNA mutations specific to tumours, not only certain
proteins on the surface of cancer cells.